Aegis and Dr Reddys sign drug delivery agreement

Published: 25-Jan-2010
Drug Delivery Finance Pharmaceutical

Will give the Indian drugmaker access to US-based Aegis\' Intravail drug delivery technology for certain drugs


Dr Reddys Laboratories and Aegis Therapeutics have agreed a partnership that will give the Indian drugmaker access to US-based Aegis' Intravail drug delivery technology for certain drugs currently being marketed with annual worldwide sales of more than US$1bn. The financial terms were not revealed.

The products under the exclusive licensing agreement will be developed, manufactured and marketed worldwide by Dr Reddys.

  • Companies:
  • Dr Reddys Laboratories
  • Aegis Therapeutics LLC
See more

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

Read more
The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Medincell collaborates with AbbVie to develop next-generation long-acting injectable therapies The partnership will focus on the development and commercialisation of six long-acting injectable therapies across various therapeutic areas
  3. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. Lonza aims to tackle bias concerns during blinded clinical trials Lonza has introduced an over-encapsulation product aimed at tackling concerns around bias during blinded clinical trials

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Pharmaceutical

Dr. Reddy’s to distribute three Amgen medicines in India

In the areas of oncology and cardiology
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Subscribe now